CANCER INCIDENCE AND MORTALITY AFTER I-131 THERAPY FOR HYPERTHYROIDISM

被引:0
|
作者
HALL, P
HOLM, LE
机构
来源
RADIATION AND PUBLIC PERCEPTION: BENEFITS AND RISKS | 1995年 / 243卷
关键词
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Cancer risk teas studied In 10,552 Swedish hyperthyroid patients treated with I-131 between 1950 and 1975. Patients were followed for an average of 15 years (range 1-35 years) and were matched with the Swedish Cancer Register (SCR) and the Swedish Cause of Death Register (SCDR). The overall standardized incidence ratio (SIR) was 1.06 [95% confidence interval (CI) = 1.01-1.11], and the overall standardized mortality ratio (SMR) was 1.09 (95% CI = 1.03-1.16). The stomach was the only site for which cancer risk increased over time (p < 0.05) and with increasing activity of I-131 administered (p = not significant). No Increased incidence of leukemia was found, which adds further support to the view that a radiation dose delivered gradually over time is less carcinogenic than the same total close received over a short time. A possible excess owing to radiation teas suggested only far stomach cancer.
引用
收藏
页码:103 / 112
页数:10
相关论文
共 50 条
  • [1] CANCER MORTALITY AFTER I-131 THERAPY FOR HYPERTHYROIDISM
    HALL, P
    BERG, G
    BJELKENGREN, G
    BOICE, JD
    ERICSSON, UB
    HALLQUIST, A
    LIDBERG, M
    LUNDELL, G
    TENNVALL, J
    WIKLUND, K
    HOLM, LE
    LINDBERG, S
    CEDERQUIST, E
    WICKLUND, H
    LARSSON, LG
    INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (06) : 886 - 890
  • [2] CANCER RISK AFTER I-131 THERAPY FOR HYPERTHYROIDISM
    HOLM, LE
    HALL, P
    WIKLUND, K
    LUNDELL, G
    BERG, G
    BJELKENGREN, G
    CEDERQUIST, E
    ERICSSON, UB
    HALLQUIST, A
    LARSSON, LG
    LIDBERG, M
    LINDBERG, S
    TENNVALL, J
    WICKLUND, H
    BOICE, JD
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (15): : 1072 - 1077
  • [3] CANCER RISK AFTER I-131 THERAPY FOR HYPERTHYROIDISM
    MEYER, MA
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (13) : 1026 - 1027
  • [4] INCIDENCE OF HYPOTHYROIDISM OCCURRING LONG AFTER I-131 THERAPY FOR HYPERTHYROIDISM
    HOLM, LE
    LUNDELL, G
    ISRAELSSON, A
    DAHLQVIST, I
    JOURNAL OF NUCLEAR MEDICINE, 1982, 23 (02) : 103 - 107
  • [5] CURE RATE AFTER I-131 THERAPY FOR HYPERTHYROIDISM
    HOLM, LE
    LUNDELL, G
    DAHLQVIST, I
    ISRAELSSON, A
    ACTA RADIOLOGICA ONCOLOGY, 1981, 20 (03): : 161 - 166
  • [6] THYROID CANCER FOLLOWING I-131 THERAPY OF HYPERTHYROIDISM
    LIMA, JB
    CATZ, B
    PERZIK, SL
    JOURNAL OF NUCLEAR MEDICINE, 1970, 11 (01) : 46 - &
  • [7] MORTALITY IN PATIENTS TREATED FOR HYPERTHYROIDISM WITH I-131
    HALL, P
    LUNDELL, G
    HOLM, LE
    ACTA ENDOCRINOLOGICA, 1993, 128 (03): : 230 - 234
  • [8] BREAST-CANCER FOLLOWING I-131 THERAPY FOR HYPERTHYROIDISM
    HOFFMAN, DA
    MCCONAHEY, WM
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1983, 70 (01) : 63 - 67
  • [10] SECONDARY EFFECTS OF I-131 THERAPY IN HYPERTHYROIDISM
    BOUILLON, R
    BECQ, H
    ACTA CLINICA BELGICA, 1984, 39 (05): : 296 - 305